PRME Prime Medicine Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRME

Price (delayed)

$3.48

Market cap

$628.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.25

Enterprise value

$665.26M

?
Relative Growth: Rel. Growth: 27
Relative Strength: Rel. Strength: 64
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 29

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime ...

Highlights
The EPS has grown by 22% YoY and by 7% from the previous quarter
PRME's debt is down by 5% year-on-year
PRME's gross profit is down by 13% from the previous quarter but it is up by 4.9% YoY
PRME's revenue is down by 13% QoQ but it is up by 4.9% YoY
Prime Medicine's equity has decreased by 37% from the previous quarter and by 28% YoY
The quick ratio has decreased by 20% from the previous quarter and by 11% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://primemedicine.com
Peers: VRTX NTLA CRSP DNLI

Key stats

What are the main financial stats of PRME

PRME stock price

How has the Prime Medicine stock price performed over time
Intraday
10.83%
1 week
2.35%
1 month
0.29%
1 year
163.64%
YTD
0.29%
QTD
0%

Financial performance

How have Prime Medicine's revenue and profit performed over time
Revenue
$4.03M
Gross profit
$4.03M
Operating income
-$206.61M
Net income
-$198.37M
Gross margin
100%
Net margin
-4,917.6%
The operating margin has declined by 14% since the previous quarter but it has grown by 4.6% year-on-year
PRME's gross profit is down by 13% from the previous quarter but it is up by 4.9% YoY
PRME's revenue is down by 13% QoQ but it is up by 4.9% YoY
PRME's net margin is down by 13% since the previous quarter but it is up by 6% year-on-year

Price vs fundamentals

How does PRME's price correlate with its fundamentals

Growth

What is Prime Medicine's growth rate over time

Valuation

What is Prime Medicine stock price valuation
P/E
N/A
P/B
8.19
P/S
152.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
164.91
The EPS has grown by 22% YoY and by 7% from the previous quarter
Prime Medicine's equity has decreased by 37% from the previous quarter and by 28% YoY
PRME's price to book (P/B) is 27% higher than its last 4 quarters average of 5.8
The P/S is 16% above the last 4 quarters average of 119.3
PRME's revenue is down by 13% QoQ but it is up by 4.9% YoY

Efficiency

How efficient is Prime Medicine business performance
The return on equity has dropped by 51% year-on-year and by 6% since the previous quarter
The return on invested capital has grown by 38% year-on-year
The ROS has contracted by 13% from the previous quarter but it has grown by 6% YoY
Prime Medicine's return on assets has increased by 8% YoY

Dividends

What is PRME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRME.

Financial health

How did Prime Medicine financials performed over time
PRME's total assets is 35% greater than its total liabilities
Prime Medicine's current ratio has decreased by 21% QoQ and by 21% YoY
The quick ratio has decreased by 20% from the previous quarter and by 11% YoY
PRME's debt is 49% greater than its equity
Prime Medicine's debt to equity has surged by 55% QoQ and by 32% YoY
Prime Medicine's equity has decreased by 37% from the previous quarter and by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.